GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting.

Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
15 Feb 2021
Historique:
entrez: 16 2 2021
pubmed: 17 2 2021
medline: 17 2 2021
Statut: aheadofprint

Résumé

Throughout 2020, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has been working to update the GRAPPA treatment recommendations for psoriasis and psoriatic arthritis (PsA). The planned methodology for this update was published previously, and herein we provide an update on progress so far, including details of the systematic literature searches undertaken. GRAPPA is committed to regular updates of its treatment recommendations to incorporate the many significant therapeutic advances that have taken place in the PsA literature since the previous recommendation publication in 2015. The development and updating of treatment recommendations for optimal treatment approaches for patients with PsA has been an important mission of the GRAPPA since its inception. GRAPPA is currently finalizing domain-specific recommendations with an aim to produce updated treatment recommendations for publication in 2021.

Identifiants

DOI: 10.3899/jrheum.201681 PMID: 33589547
pubmed: 33589547
pii: jrheum.201681
doi: 10.3899/jrheum.201681
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Laura C Coates (LC)

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, La Jolla, California, USA. LCC has received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, and honoraria or consulting fees from AbbVie, Amgen, Biogen, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB. ERS has received grant/research support from AbbVie, BMS, Janssen, Novartis, Pfizer, Roche, and UCB, and honoraria or consulting fees from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB. AK has received grant/research support from AbbVie, Amgen, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, and honoraria and/or consulting fees from AbbVie, Boehringer-Ingelheim, BMS, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB. NC and DAvdW have no conflicts of interest. Address correspondence to Dr. A. Kavanaugh, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92037-0943, USA. Email: akavanaugh@health.ucsd.edu.
ORCID: 0000-0002-4756-663X

Nadia Corp (N)

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, La Jolla, California, USA. LCC has received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, and honoraria or consulting fees from AbbVie, Amgen, Biogen, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB. ERS has received grant/research support from AbbVie, BMS, Janssen, Novartis, Pfizer, Roche, and UCB, and honoraria or consulting fees from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB. AK has received grant/research support from AbbVie, Amgen, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, and honoraria and/or consulting fees from AbbVie, Boehringer-Ingelheim, BMS, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB. NC and DAvdW have no conflicts of interest. Address correspondence to Dr. A. Kavanaugh, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92037-0943, USA. Email: akavanaugh@health.ucsd.edu.
ORCID: 0000-0002-6758-9513

Danielle A van der Windt (DA)

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, La Jolla, California, USA. LCC has received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, and honoraria or consulting fees from AbbVie, Amgen, Biogen, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB. ERS has received grant/research support from AbbVie, BMS, Janssen, Novartis, Pfizer, Roche, and UCB, and honoraria or consulting fees from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB. AK has received grant/research support from AbbVie, Amgen, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, and honoraria and/or consulting fees from AbbVie, Boehringer-Ingelheim, BMS, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB. NC and DAvdW have no conflicts of interest. Address correspondence to Dr. A. Kavanaugh, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92037-0943, USA. Email: akavanaugh@health.ucsd.edu.
ORCID: 0000-0002-7248-6703

Enrique R Soriano (ER)

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, La Jolla, California, USA. LCC has received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, and honoraria or consulting fees from AbbVie, Amgen, Biogen, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB. ERS has received grant/research support from AbbVie, BMS, Janssen, Novartis, Pfizer, Roche, and UCB, and honoraria or consulting fees from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB. AK has received grant/research support from AbbVie, Amgen, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, and honoraria and/or consulting fees from AbbVie, Boehringer-Ingelheim, BMS, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB. NC and DAvdW have no conflicts of interest. Address correspondence to Dr. A. Kavanaugh, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92037-0943, USA. Email: akavanaugh@health.ucsd.edu.
ORCID: 0000-0003-3143-1084

Arthur Kavanaugh (A)

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, La Jolla, California, USA. LCC has received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, and honoraria or consulting fees from AbbVie, Amgen, Biogen, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB. ERS has received grant/research support from AbbVie, BMS, Janssen, Novartis, Pfizer, Roche, and UCB, and honoraria or consulting fees from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB. AK has received grant/research support from AbbVie, Amgen, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, and honoraria and/or consulting fees from AbbVie, Boehringer-Ingelheim, BMS, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB. NC and DAvdW have no conflicts of interest. Address correspondence to Dr. A. Kavanaugh, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92037-0943, USA. Email: akavanaugh@health.ucsd.edu.
ORCID: 0000-0001-6942-5830

Classifications MeSH